Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations

This publication has 21 references indexed in Scilit:

• Polynuclear Platinum Drugs
  Published by Taylor & Francis ,2004
• A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)
  British Journal of Cancer, 2003
• Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin
  European Journal Of Cancer, 2002
• An update on satraplatin: the first orally available platinum anticancer drug
  Expert Opinion on Investigational Drugs, 2000
• Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin
  British Journal of Cancer, 1999
• Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
  Annals of Oncology, 1998
• Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
  European Journal Of Cancer, 1997
• Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
  European Journal Of Cancer, 1993
• Carboplatin in combination therapy for ovarian cancer
  Cancer Treatment Reviews, 1988
• Platinum Compounds: a New Class of Potent Antitumour Agents
  Nature, 1969